Shares of Theralase Technologies Inc. (CVE:TLT – Get Free Report) hit a new 52-week low on Monday . The stock traded as low as C$0.15 and last traded at C$0.16, with a volume of 381577 shares traded. The stock had previously closed at C$0.16.
Theralase Technologies Stock Performance
The business’s 50-day simple moving average is C$0.19 and its two-hundred day simple moving average is C$0.19. The firm has a market capitalization of C$39.84 million, a price-to-earnings ratio of -8.61 and a beta of -0.45. The company has a quick ratio of 3.40, a current ratio of 1.91 and a debt-to-equity ratio of 14.85.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Further Reading
- Five stocks we like better than Theralase Technologies
- What is the Dogs of the Dow Strategy? Overview and Examples
- The Vertiv Pullback: Ignore the Noise, Buy the Data
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Insiders Buy Natural Gas Stocks: 2 for the Watchlist
- What does consumer price index measure?
- Rivian’s Autonomy Bombshell Changes Everything—Even Its Valuation
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
